FASE II STUDY WITH BORTEZOMIB, RITUXIMAB AND BENDAMUSTIN -BRB- FOR NON-HODGKIN LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIAS PATIENTS AT FIRST RELAPSE
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Rituximab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 15 Sep 2017 Planned number of patients changed from 61 to 38.
- 16 Mar 2017 Planned End Date changed from 1 Jul 2018 to 1 Dec 2020.
- 16 Mar 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Apr 2018.